Sutro Biopharma, Inc.
NASDAQ:STROBiotechnology
+$0.32 today
- Market cap
- $141.11M
- Beta
- 1.55
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$1,174.12
Volume 0.31M
Average 0.28M
STRO Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Sutro Biopharma, Inc.NASDAQ: STRO
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $7.58M fell 42.9% year over year, behind the -27.9% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 12.4% from the prior quarter. Over 3 fiscal years it compounded at -11.7% a year.
Context
- Selling, general & admin amounted to 40.0% of revenue in FY2025, down 38.1 pp from a year earlier.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 9 analysts of $32.4M (-21.0%) for the fiscal year ending Dec 2026, a slowdown from the -15.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $7.58M-12.4% QoQ
- Last fiscal yearDec 2025
- $41.02M-15.3% YoY
- LTMMar 2026
- $35.33M-27.9% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 41.02M USD
- Year-over-year change
- -15.3%
- 4-year CAGR
- -7.5%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 41.02M | -15.3% |
| FY2024 | 2024-12-31 | 48.45M | -22.6% |
| FY2023 | 2023-12-31 | 62.58M | +5.1% |
| FY2022 | 2022-12-31 | 59.54M | +6.3% |
| FY2021 | 2021-12-31 | 56M | — |
Selling, General & Admin vs competitors
How STRO compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -27.9% is the 6th highest of 8, against a peer median of -13.9%.
- Selling, general & admin amounts to 35.5% of revenue for STRO, versus a peer median of 16758.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $39.91M USD | -32.7% | +5.7% | — | |
| LTM Mar 2026 | $35.33M USD | -27.9% | -11.7% | 35.5% | |
| LTM Mar 2026 | $30.49M USD | -13.9% | -7.9% | 67.6% | |
| FY2025 | $20.34M USD | +5.8% | -0.8% | 31781.3% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $20.27M USD | +8.2% | -0.8% | — |
| LTM Mar 2026 | $17.37M USD | -6.9% | -4.3% | 1736.5% | |
| LTM Mar 2026 | $17.25M USD | — | +15.2% | — | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $15.32M USD | -41.8% | +90.0% | — |
| LTM Mar 2026 | €14.24M EUR | -27.6% | +7.0% | 48538.7% | |
| Peer median (excluding STRO) | — | -13.9% | +2.5% | 16758.9% | |
Competitors are the stored peer set for STRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 61.88M | 67.77M | 153.73M | 62.04M | 102.48M |
| Cost of Revenue | 9.77M | 8.29M | 6.82M | 7.22M | 7.32M |
| Gross Profit | 52.11M | 59.48M | 146.92M | 54.83M | 95.16M |
| Gross Margin | 84.2% | 87.8% | 95.6% | 88.4% | 92.9% |
| Research & Development | 104.4M | 137.17M | 180.43M | 252.04M | 166.42M |
| Selling, General & Admin | 56M | 59.54M | 62.58M | 48.45M | 41.02M |
| Operating Expenses | 150.63M | 188.43M | 236.19M | 293.28M | 200.11M |
| Depreciation & Amortization | 4.84M | 8.29M | 6.82M | 7.22M | 7.32M |
| EBITDA | (97.56M) | (105.07M) | (67.92M) | (180.45M) | (145.65M) |
| EBITDA Margin | -157.7% | -155.0% | -44.2% | -290.9% | -142.1% |
| Operating Income | (98.52M) | (128.94M) | (89.28M) | (238.45M) | (104.95M) |
| Operating Margin | -159.2% | -190.3% | -58.1% | -384.3% | -102.4% |
| Interest Income | 577K | 3.46M | 14.51M | 44.43M | 9.25M |
| Interest Expense | 3.14M | 3.35M | 23.75M | 31.07M | 38.21M |
| Other Income / Expenses | (7.01M) | 12.24M | 677K | 13.36M | (86.23M) |
| Income Before Tax | (105.54M) | (116.7M) | (88.6M) | (225.1M) | (191.18M) |
| Pre-Tax Margin | -170.6% | -172.2% | -57.6% | -362.8% | -186.5% |
| Income Tax Expense | 0 | 2.5M | 18.19M | 2.36M | (93K) |
| Net Income | (105.54M) | (119.2M) | (106.79M) | (227.46M) | (191.09M) |
| Net Margin | -170.6% | -175.9% | -69.5% | -366.6% | -186.5% |
| EPS (Basic) | (22.90) | (23.50) | (17.80) | (29.60) | (22.49) |
| EPS (Diluted) | (22.90) | (23.50) | (17.80) | (29.60) | (22.49) |
| Weighted Avg Shares | 4.61M | 5.07M | 6.02M | 7.68M | 8.5M |
| Weighted Avg Shares (Diluted) | 4.61M | 5.07M | 6.02M | 7.68M | 8.5M |
Sutro Biopharma, Inc.
NASDAQ:STRO
Intrinsic Alpha fair value
Locked
Current Price
$8.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.